share_log

EyePoint Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Adage Capital Management, L.P.(10.35%),Robert Atchinson(10.35%), etc.

EyePoint Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Adage Capital Management, L.P.(10.35%),Robert Atchinson(10.35%), etc.

EyePoint Pharmaceuticals | SC 13G：超過5%持股股東披露文件-Adage Capital Management, L.P.(10.35%),Robert Atchinson(10.35%)等
美股sec公告 ·  04/30 20:57
Moomoo AI 已提取核心訊息
EyePoint Pharmaceuticals, Inc. has been the subject of a Schedule 13G filing with the Securities and Exchange Commission, indicating a significant investment by Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross. The filing, dated April 30, 2024, reports that Adage Capital Management, L.P., along with Atchinson and Gross, collectively hold 5,156,299 shares of EyePoint Pharmaceuticals' common stock, which represents 10.35% of the company's class of securities. This level of ownership classifies them as major shareholders, as they own more than 5% of the company's common stock. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934, which is typically used by passive investors. The address for the principal business office of the reporting persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. The filing emphasizes that the acquisition of the shares is in the ordinary course of business and not with the purpose of changing or influencing the control of EyePoint Pharmaceuticals.
EyePoint Pharmaceuticals, Inc. has been the subject of a Schedule 13G filing with the Securities and Exchange Commission, indicating a significant investment by Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross. The filing, dated April 30, 2024, reports that Adage Capital Management, L.P., along with Atchinson and Gross, collectively hold 5,156,299 shares of EyePoint Pharmaceuticals' common stock, which represents 10.35% of the company's class of securities. This level of ownership classifies them as major shareholders, as they own more than 5% of the company's common stock. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934, which is typically used by passive investors. The address for the principal business office of the reporting persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. The filing emphasizes that the acquisition of the shares is in the ordinary course of business and not with the purpose of changing or influencing the control of EyePoint Pharmaceuticals.
EyePoint Pharmicals, Inc.一直是向美國證券交易委員會提交的附表13G文件的主體，這表明Adage Capital Management, L.P. 以及個人羅伯特·阿欽森和菲利普·格羅斯進行了大量投資。這份日期爲2024年4月30日的文件顯示，Adage Capital Management, L.P. 以及阿欽森和格羅斯共持有EyePoint Pharmaceuticals普通股的5,156,299股，佔該公司證券類別的10.35％。這種所有權水平將他們歸類爲主要股東，因爲他們擁有公司5％以上的普通股。這些股份以共同的投票權和處置權持有。該文件是根據1934年《證券交易法》第13d-1（b）條提交的，該法通常由被動投資者使用。申報人主要業務辦公室的地址是馬薩諸塞州波士頓克拉倫登街200號52樓02116。該文件強調，收購這些股份屬於正常業務流程，其目的不是改變或影響EyePoint Pharmicals的控制權。
EyePoint Pharmicals, Inc.一直是向美國證券交易委員會提交的附表13G文件的主體，這表明Adage Capital Management, L.P. 以及個人羅伯特·阿欽森和菲利普·格羅斯進行了大量投資。這份日期爲2024年4月30日的文件顯示，Adage Capital Management, L.P. 以及阿欽森和格羅斯共持有EyePoint Pharmaceuticals普通股的5,156,299股，佔該公司證券類別的10.35％。這種所有權水平將他們歸類爲主要股東，因爲他們擁有公司5％以上的普通股。這些股份以共同的投票權和處置權持有。該文件是根據1934年《證券交易法》第13d-1（b）條提交的，該法通常由被動投資者使用。申報人主要業務辦公室的地址是馬薩諸塞州波士頓克拉倫登街200號52樓02116。該文件強調，收購這些股份屬於正常業務流程，其目的不是改變或影響EyePoint Pharmicals的控制權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息